2020
DOI: 10.21115/jbes.v12.n2.p155-63
|View full text |Cite
|
Sign up to set email alerts
|

Avaliação crítica de estudos de custo-efetividade de medicamentos oncológicos recomendados para incorporação pela Conitec no Brasil

Abstract: Financiamento: Este estudo não recebeu qualquer tipo de financiamento. Conflito de interesses: Os autores declaram que não há nenhum conflito de interesse para a realização deste trabalho.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 13 publications
0
1
0
Order By: Relevance
“…The RENAME update proposed by CONITEC consists of: "i) a reactive process in which the claimants are bodies and institutions, public or private, or individuals; and ii) an active process conducted by a CONITEC subcommitteethe Technical Subcommittee for Updating RENAME and the National Therapeutic Form. " In both processes, medicines, and inputs are included, excluded, or changed in the SUS after evaluation by CONITEC and a decision by the Department of Science, Technology, Innovation and Strategic Health Inputs of the Ministry of Health (BRASIL, C. 2020;BRASIL, MS. 2022;RIBEIRO, 2020).…”
mentioning
confidence: 99%
“…The RENAME update proposed by CONITEC consists of: "i) a reactive process in which the claimants are bodies and institutions, public or private, or individuals; and ii) an active process conducted by a CONITEC subcommitteethe Technical Subcommittee for Updating RENAME and the National Therapeutic Form. " In both processes, medicines, and inputs are included, excluded, or changed in the SUS after evaluation by CONITEC and a decision by the Department of Science, Technology, Innovation and Strategic Health Inputs of the Ministry of Health (BRASIL, C. 2020;BRASIL, MS. 2022;RIBEIRO, 2020).…”
mentioning
confidence: 99%